Previous 10 | Next 10 |
JPMorgan analyst Anupam Rama says Mirati Therapeutics ( MRTX +1% ) may experience volatility related to Amgen's ( AMGN +0.5% ) fortunes with pipeline candidate AMG 510, in early-stage development for certain types of cancer. More news on: Mirati Therapeutics, Inc., Amgen Inc....
Mirati Therapeutics (NASDAQ: MRTX ): Q1 GAAP EPS of -$1.17. More news on: Mirati Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
SAN DIEGO , April 29, 2019 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today reported financial results for the first quarter ended March 31, 2019 . First Quarter Highlights January 7 th , we announced a clinical collabor...
Source: Shutterstock The stock market has continued to edge higher and the two major indexes, the Nasdaq ( QQQ ) and S&P 500 ( SPY ), touched the all-time high milestone last week. The steady gain reflects a diminishing concern relating to the pace of a global economic slowdown, as m...
Gainers: ATAI +29.3% . MRTX +3.1% . KALA +3.1% . HPE +2.4% . PKD +2.1% . More news on: ATA Inc., Mirati Therapeutics, Inc., Kala Pharmaceuticals, Inc., Stocks on the move, Read more ...
Gainers: PHAS +31.6% . GWPH +4.1% . RUHN +2.9% . IGC +1.9% . SENS +1.9% . More news on: PhaseBio Pharmaceuticals, Inc., GW Pharmaceuticals plc, Hangzhou Ruhnn Holding Co.,Ltd, Stocks on the move, Read more ...
SAN DIEGO , April 1, 2019 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical stage targeted oncology company, will present at the H.C. Wainwright & Co. Global Life Sciences Conference in London, England on Monday, April 8 th at 11:30am BST / 6:30am ET / 3:...
(Rendition of Brain Neurons, Source: NIH) The biotech sector has continued to participate in the market rally. One of the reasons is the strength in biopharma M&A activity, which provides unique support for valuations and particularly assists the small-and-midcap biotech companies. We ...
The following slide deck was published by Mirati Therapeutics, Inc. in conjunction with this Read more ...
SAN DIEGO , March 5, 2019 Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical stage targeted oncology company, will present at two upcoming healthcare conferences. Cowen 39 th Annual Healthcare Conference in Boston on Tuesday, March 12 th at 11:20 a.m. ET / 8:20 a.m. PT . O...
News, Short Squeeze, Breakout and More Instantly...
Mirati Therapeutics Inc. Company Name:
MRTX Stock Symbol:
NASDAQ Market:
Mirati Therapeutics Inc. Website:
First Solar Inc. (FSLR) is expected to report $3.19 for Q4 2023 VIZIO Holding Corp. Class A (VZIO) is expected to report $0.02 for Q4 2023 Henry Schein Inc. (HSIC) is expected to report $0.71 for Q4 2023 Republic Services Inc. (RSG) is expected to report $1.28 for Q4 2023 Forge Gl...
European Commission Approves KRAZATI (adagrasib) as a Targeted Treatment Option for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with a KRASG12C Mutation PR Newswire SAN DIEGO and ZUG, Switzerland , Jan. 10, 2024 /PRNewswire/ -- Mirati The...
2023-12-18 23:40:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...